Topimax Filmuhúðuð tafla 25 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

topimax filmuhúðuð tafla 25 mg

janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 25 mg

Topimax Filmuhúðuð tafla 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

topimax filmuhúðuð tafla 50 mg

janssen-cilag ab - topiramatum inn - filmuhúðuð tafla - 50 mg

Topimax Hart hylki 15 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

topimax hart hylki 15 mg

janssen-cilag ab - topiramatum inn - hart hylki - 15 mg

Topiramat Actavis Filmuhúðuð tafla 100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

topiramat actavis filmuhúðuð tafla 100 mg

actavis group ptc ehf. - topiramatum inn - filmuhúðuð tafla - 100 mg

Topiramat Actavis Filmuhúðuð tafla 25 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

topiramat actavis filmuhúðuð tafla 25 mg

actavis group ptc ehf. - topiramatum inn - filmuhúðuð tafla - 25 mg

Topiramat Actavis Filmuhúðuð tafla 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

topiramat actavis filmuhúðuð tafla 50 mg

actavis group ptc ehf. - topiramatum inn - filmuhúðuð tafla - 50 mg

Topiramate Alvogen (Topiramate Portfarma) Filmuhúðuð tafla 25 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

topiramate alvogen (topiramate portfarma) filmuhúðuð tafla 25 mg

alvogen ehf. - topiramatum inn - filmuhúðuð tafla - 25 mg

Topiramate Alvogen (Topiramate Portfarma) Filmuhúðuð tafla 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

topiramate alvogen (topiramate portfarma) filmuhúðuð tafla 50 mg

alvogen ehf. - topiramatum inn - filmuhúðuð tafla - 50 mg

Orserdu Evrópusambandið - íslenska - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Zomarist Evrópusambandið - íslenska - EMA (European Medicines Agency)

zomarist

novartis europharm limited  - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - lyf notuð við sykursýki - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.